Market revenue in 2023 | USD 266.6 million |
Market revenue in 2030 | USD 430.7 million |
Growth rate | 7.1% (CAGR from 2023 to 2030) |
Largest segment | Toxicology testing |
Fastest growing segment | Bioanalysis and DMPK studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology |
Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Toxicology testing was the largest segment with a revenue share of 26.14% in 2023. Horizon Databook has segmented the France preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.
An efficient healthcare & reimbursement system and a large patient pool made the country a preferred location for outsourcing clinical trials. There are hospitals specializing in management of patients undergoing clinical trials across the country.
Moreover, the government is also taking active measures to reduce the approval time of drugs in the clinical trials, which is likely to enhance the market growth. The presence of key pharmaceutical companies like Sanofi, Roche, and Novartis in the country further contributes to the market growth in France.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account